Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

REPORT OF SAFETY OF THE USE OF A SHORT 32G NEEDLE FOR INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINOPATHY OF PREMATURITY: A Multicenter Study

Cernichiaro-Espinosa, Linda, A., MD*; Harper, Clio, A., III, MD†,‡,§; Read, Sarah, P., MD, PhD*; Wright, Lauren, M., MD; Scribbick, Frank, W., III, MD; Young, Ryan, MD; Negron, Catherin, I., MBA*; Rodríguez, Ana, RN, RRT; Berrocal, Audina, M., MD*,¶

doi: 10.1097/IAE.0000000000002172
New Instruments

*Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine, Miami, Florida;

Department of Ophthalmology, University of Texas Health Science Center, San Antonio, Texas;

Austin Retina Associates, Austin, Texas;

§Department of Surgery and Perioperative Services, Dell Medical School, University of Texas, Austin, Texas; and

Neonatal Intensive Care Unit, Holtz Children's Hospital, Jackson Health System, University of Miami, Miami, Florida.

Reprint requests: Audina M. Berrocal, MD, Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine, 900 NW 17th Avenue, Miami, FL 33136; e-mail: aberrocal@med.miami.edu

A. M. Berrocal is a consultant of Alcon, Inc (CA); Dorc (Dutch Ophthalmic Research Center International BV, Holland) and Visunex Medical Systems (CA) unrelated to this publication. The remaining authors have no financial/conflicting interests to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.retinajournal.com).

© 2018 by Ophthalmic Communications Society, Inc.